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Abstract Electrochemotherapy is an effective antitumor
treatment currently applied to cutaneous and subcutaneous
tumors. Electrochemotherapy of tumors located close to the
heart could lead to adverse effects, especially if electro-
poration pulses were delivered within the vulnerable period
of the heart or if they coincided with arrhythmias of some
types. We examined the inﬂuence of electroporation pulses
on functioning of the heart of human patients by analyzing
the electrocardiogram. We found no pathological mor-
phological changes in the electrocardiogram; however, we
demonstrated a transient RR interval decrease after
application of electroporation pulses. Although no adverse
effects due to electroporation have been reported so far, the
probability for complications could increase in treatment of
internal tumors, in tumor ablation by irreversible electro-
poration, and when using pulses of longer durations. We
evaluated the performance of our algorithm for syn-
chronization of electroporation pulse delivery with
electrocardiogram. The application of this algorithm in
clinical electroporation would increase the level of safety
for the patient and suitability of electroporation for use in
anatomical locations presently not accessible to existing
electroporation devices and electrodes.
Keywords Electrochemotherapy   Electrocardiogram  
QRS detection   Synchronization of electroporation pulse
delivery with ECG
1 Introduction
The combined treatment in which delivery of chemothera-
peutic drug is followed by application of high-voltage
electric pulses locally to the tumor has been termed electr-
ochemotherapy. The effect of local electropermeabilization
of the cell membrane (the disruption of the lipid matrix and
creation of aqueous pathways [10, 38]), also termed elec-
troporation,transientlyenablestheentryofanticancerdrugs,
such as bleomycin or cisplatin, into the cells and hence
greater effectiveness of tumor treatment. Electroche-
motherapy has been successfully used for treatment of
cutaneous and subcutaneous tumors irrespective of their
histological origin in different animal tumor models and in
humans [19, 36, 51, 52]. In these studies, a typical electr-
ochemotherapy protocol involved eight electroporation
pulses(EPpulses)withamplitudeofabout1,000 V,duration
100 ls, repetition frequency 1 Hz, and inter-electrode dis-
tance 8 mm. However, the protocol involving eight EP
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and is currently replacing the 1-Hz protocol due to a lesser
discomfort and pain inﬂicted to patients [31, 57]. Electrodes
of three different conﬁgurations can be used for EP pulse
delivery during electrochemotherapy. EP pulses applied by
plate electrodes areusedincaseofsuperﬁcialtumornodules
whereas EP pulses to deeper-seated tumors (subcutaneous
nodules)areappliedusingneedlerowarrayelectrodes(eight
needleelectrodesarrangedintworows)orneedlehexagonal
array electrodes (six hexagonally arranged electrodes with
the seventh electrode in the centre) [31]. The number of
applied EP pulses and pulse repetition frequency depend on
the electrode type and deﬁne the duration ofelectroporation,
which is 1.6 ms for plate and needle row array electrodes
[31] and approximately 200 ms for needle hexagonal array
electrodes [31, 45]. New protocols for delivery of EP pulses
are either already in use or are being developed. For gene
electrotransfer three different EP pulse protocols are in use:
short high-voltage EP pulses, EP pulses of a much longer
duration (in the order of milliseconds), or combination of
short high-voltage EP pulses with very long low-voltage
electrophoretic pulses (amplitude 50–100 V, duration
100 ms) [8, 18, 20, 40, 48]. Tumor ablation by irreversible
electroporation is another recently developed application,
where EP pulses with larger amplitudes (up to 3,000 V) and
longer durations (up to 24 ms) are delivered [3, 14, 28, 35].
New applications using endoscopic or surgical means to
access internal tumors are also being developed [21].
Electrochemotherapy is reported as an efﬁcient and safe
method. No adverse effects have been reported so far.
Electrochemotherapy causes only minor side effects in the
patients such as the transient lesions in areas in direct
contact with the electrodes [37] and acute localized pain
due to contraction of muscles in vicinity of the electrodes
[36, 57]. The induced contraction could present a problem
if provoked in the heart muscle [46]. There is very little
chance that currently used electroporation protocols could
interfere with functioning of the heart since there is no such
practical evidence. However, this issue has not been sys-
tematically investigated yet. Given the increasing need for
palliative treatment of internal tumors, the possibility of EP
pulses interfering with functioning of the heart is emerging
for tumors located close to the heart muscle. Among pos-
sible irregularities of functioning of the heart that the
application of EP pulses could induce (e.g., atrial and
ventricular ﬂutter and ﬁbrillation, premature heartbeats),
the most dangerous is ventricular ﬁbrillation [46]. Fibril-
lation can be induced if electrical stimulus is delivered
during late atrial or ventricular systole, during the so-called
vulnerable period of the heart [25, 46, 55] (Fig. 1). For
ventricular myocardium, the vulnerable period coincides
with the middle and terminal phases of the T wave [46], but
higher shock strengths cause the vulnerable period to occur
several milliseconds earlier in the heartbeat [27]; therefore,
the whole T wave can be considered to be within the
vulnerable period of the ventricles. For the atria, the vul-
nerable period is somewhere in the S wave [46]. Externally
applied electric pulses delivered outside the vulnerable
period have extremely low probability of inducing ven-
tricular ﬁbrillation [46]. According to this fact the
synchronization of EP pulse delivery with electrocardio-
gram (ECG) would increase safety of the patient. The
likelihood of electroporation to inﬂuence functioning of the
heart depends also on applied pulse voltage, duration,
number and repetition frequency of EP pulses, and electric
current pathway [46].
Although ﬁbrillation can occur in normal and healthy
hearts, it is more likely in hearts with structural or func-
tional abnormalities [11]. Abnormalities of the heart
rhythm (arrhythmias) are indicated by signiﬁcant deviation
of RR interval from its normal value [12, 46]. During some
arrhythmias the heart becomes more susceptible to external
stimuli due to a decreased threshold level for ﬁbrillation.
Therefore EP pulses coinciding with some arrhythmias
could elicit ﬁbrillation. This potential danger is most sig-
niﬁcant after premature heartbeat, the extrasystole [46].
The main purpose of this study was therefore to inves-
tigate the possible effects of EP pulses on functioning of
the heart and to address the relevance of synchronization of
EP pulse delivery with ECG. In this context we also
evaluated the performance of our previously developed
algorithm for QRS detection and synchronization of EP
pulse delivery with ECG [30].
2 Methods and materials
2.1 Patients and electrochemotherapy
Fourteen human patients were included in this study.
Before electrochemotherapy treatment a signed consent
was obtained from each patient. Patients were treated
Fig. 1 The vulnerable period and characteristics of a typical
heartbeat
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123according to the electrochemotherapy protocols as descri-
bed by Marty et al. [31] with the addition of ECG monitor-
ing. Electrochemotherapy drugs (cisplatin or bleomycin)
were administered locally to tumors. EP pulses were
generated by the electric pulse generator Cliniporator
TM
(IGEA S.R.L., Carpi, Italy). Altogether 93 applications
of EP pulses were performed. Main characteristics of the
patients, tumors and electrochemotherapy are presented in
Table 1.
We recorded 16 ECG signals on 14 patients during
electrochemotherapy at the Institute of Oncology in
Ljubljana. Two patients were treated twice. Thus ECG
signals number 1 and 2 belong to the same person as well
as signals number 5 and 6 (Table 1). ECG signals were
acquired at sampling frequency of 250 Hz using a BIOPAC
data acquisition and measurement system (BIOPAC
Systems, Inc., USA). To enable early detection of QRS
complex we required an ECG lead, which results in a
distinctive ascendant QR junction, high R wave amplitude
and high dynamics within the QRS complex in comparison
to other parts of the ECG signal. Typical standard ECG
leads fulﬁlling these requirements include the chest lead V4
and standard limb leads I, II and III. We recorded ECG
signals from leads I and III by placing the electrodes
(disposable soft cloth ECG electrodes, diameter 6 cm,
3M
TM Red Dot
TM) on wrists and ankles and computed the
third limb lead II by summing the leads I and III. The lead
with best dynamic characteristics was selected for the
analysis individually for each patient (see Table 5).
2.2 Analysis of electrocardiograms
The primary analysis of ECG signals recorded during
electrochemotherapy was made by using QRS detection
algorithm based on the analysis of a single lead ECG,
which enables EP pulse delivery prior to the vulnerable
period of the heart [30]. This algorithm for synchronization
of EP pulse delivery with ECG was developed and evalu-
ated using records of the Long-term ST database (LTST
DB database) [23] and was written in ANSI C program-
ming language. The algorithm is described in detail
elsewhere [30]. Brieﬂy, it consists of two major compo-
nents (the detection phase and the decision-making phase),
which are preceded by the learning phase during which
architecture parameters are estimated from the ECG signal.
The detection phase is based on consideration of several
ECG signal features: the QR interval, the R wave ampli-
tude and the RR interval (see Fig. 1), in order to achieve a
reliable QRS detector performance and to assure clear
distinction between normal and abnormal individual
heartbeats. For implementation of such a detector the peaks
of Q and R waves and the isoelectric level are extracted
from the ECG signal. During the decision-making phase, a
decision is made whether the EP pulse can be delivered or
not based on evaluating deviations of R wave amplitude
and RR interval of individual heartbeat from moving
average values of these two parameters.
Further analysis of ECG signals recorded during
electrochemotherapy was performed to estimate the effect
of EP pulse delivery on ECG. For this purpose the peaks of
S waves and ends of QRS complexes were determined
using program routines written in Matlab. Since the longest
normal duration of the QRS complex is 120 ms [22] and
the R peak is located approximately at the centre of the
QRS complex, it is reasonable to expect the S peak within
an interval of 60-ms after the R peak. The algorithm cal-
culates the ﬁrst derivative of the ECG signal in this 60 ms
interval and looks for the ﬁrst occurrence of three succes-
sive samples with negative ﬁrst derivative followed by a
sample with nonnegative derivative. The S peak is assigned
to the third of these four samples. Next, the algorithm
searches for the ﬂattest part of the ST segment in order to
determine the end of the QRS complex. For this purpose an
interval of 40 ms after the S peak is analyzed. The average
value of ﬁve successive samples from this interval having
the minimal total deviation from their average value is
taken as the ﬂattest part of the ST segment and the middle
sample is considered as the end of QRS complex, i.e., the
end of QRS interval. After this, the area under the QRS
complex is estimated. A similar routine is used for locali-
zation of the end of T wave except that an interval of
130 ms after the T peak is analyzed; the ﬂattest part is
searched for and the middle sample of this ﬂattest part is
considered as the end of T wave. The corrected QT interval
(QTc interval) is calculated as the QT interval divided by
the square root of the corresponding RR interval.
For evaluation of the effects of EP pulse delivery on
functioning of the heart we calculated the average values of
RR interval, QRS interval, QTc interval, QRS area and R
wave amplitude before and after the application of EP
pulses. The length of the averaging interval (8.5 s) was
chosen based on the minimum interval between two suc-
cessive applications of EP pulses, which was 8.5 s.
Testing and evaluation of this newly developed part of
the algorithm was performed by manual veriﬁcation of
automatically deﬁned locations of S peak, T peak, the end
of T wave, and duration of QRS interval on randomly
selected sequences of ECG signals included in our study. In
addition, since this was the ﬁrst application of the newly
developed part algorithm, we also manually veriﬁed the
results of the algorithm on 8.5 s-long segments of ECG
signals before and after all 93 applications of EP pulses.
AllECGsignalsweremanuallyexaminedbytwomedical
doctors (including a cardiologist), who classiﬁed all abnor-
mal heartbeats present in the signals. Other heartbeats were
considered as normal.They found no evidence of signiﬁcant
Med Biol Eng Comput (2008) 46:745–757 747
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123long-lasting heart arrhythmias (e.g., bradycardia, tachycar-
dia). For evaluation of QRS complex detection, we
calculated the following scores for each record: Nd, TP, FN
and FP (for deﬁnitions see Table 5). Based on these scores
obtainedwithabeat-by-beatcomparisonoftheresultsofour
algorithm [30] with the medical expert-deﬁned annotations
of the heartbeats, we calculated standard performance
measures of the algorithm: the sensitivity (Se), the positive
predictivity(+P)andthedetection errorrate(DER)forQRS
detection (Eqs. 1–3, respectively). The performance mea-
sures for an ideal QRS detector would be Se = 100%,
+P = 100% and DER = 0%.
Seð%Þ¼
TP
Nd
  100 ð1Þ
þPð%Þ¼
TP
TP þ FP
  100 ð2Þ
DERð%Þ¼
FP þ FN
Nd
  100 ð3Þ
For evaluation of EP pulse delivery we calculated the
following scores for each record: Np, TPp, FNp and FPp
(for deﬁnitions see Table 5). Based on these scores and in
the absence of any standard performance metrics for EP
pulse delivery, we calculated the performance measures
analogous to QRS detection metrics: the sensitivity (Sep),
the positive predictivity (+Pp) and the delivery error rate
(DERp) for EP pulses. The performance measures for an
ideal algorithm for EP pulse delivery would be Sep =
100%, +Pp = 100% and DERp = 0%.
The performance of our algorithm for QRS detection and
EP pulse delivery has previously been evaluated on ECG
signals from a standard LTST DB database [30]. The results
were: Se = 99.4%, +P = 100.0%, DER = 0.6%, Sep =
91.8%, +Pp = 100.0% and DERp = 8.3% (median values).
2.3 Numerical modeling
We performed numerical calculations of electric ﬁeld and
current distribution for tissue models. The geometry of
models and electrode conﬁgurations are shown in Fig. 2.
The modeled conditions (needle row array, needle hexag-
onal array and plate electrode conﬁgurations and voltages
applied) were the same as actually used in clinical electr-
ochemotherapy (see Tables 3 and 4 for details). The
modeled tissues (the target tumor tissue and the sur-
rounding healthy tissue) are treated as isotropic materials
with ohmic behavior (only conductivity of the tissues was
taken into account). The assigned conductivity values were
set to be 0.4 S/m for the tumor and 0.2 S/m for the healthy
tissue according to previous measurements of tumor and
tissue conductivity [34], models of subcutaneous tumor and
skin electropermeabilization [43], a 3D ﬁnite element
model of thorax, where the sensitivity of deﬁbrillation
parameters to the variations in model inhomogeneity and
approximation of skeletal muscle anisotropy was examined
for different paddle placements [9], and average con-
ductivity of tissues composing the thorax [26]. The
conductivity of cardiac muscle was reported to be in the
range between 0.17 and 0.25 S/m [9, 26]. The assigned
conductivity values for target tumor tissue (0.4 S/m) and
the surrounding healthy tissue (0.2 S/m) describe the con-
ductivity at the end of the electropermeabilization process,
thus incorporating the changes to tissue conductivity due to
exposure to external electric pulses.
The critical depth for electric ﬁeld of 200 and 450 V/cm
(value for reversible and irreversible electroporation of the
muscle, respectively [43]), by solving the Laplace equa-
tion, and the critical depth for current of 100 mA (threshold
for ventricular ﬁbrillation for 500 ls-long electrical stim-
ulus [46]), were estimated by means of ﬁnite element
method using COMSOL Multiphysics 3.3 software pack-
age (COMSOL AB, Sweden). Of the total electric current
ﬂowing through the tissue during the EP pulse delivery, no
more than 100 mA (the threshold value for ﬁbrillation) is
allowed to ﬂow through the heart. Therefore we deﬁned the
critical depth as a distance from the surface of the body (at
the site of EP delivery) below which the total electric
current ﬂowing is equal to this threshold value. This is a
very conservative approach in which it is assumed that the
entire current ﬂowing below the critical depth actually
passes through the heart. The validity of the model is
further discussed in the Sect. 4.1.
2.4 Statistical analysis
The performance of the algorithm and average values of
heartbeat parameters were compared using either the
Mann–Whitney Rank Sum or Wilcoxon Signed Rank test.
In all tests, a p value of less than 0.05 was considered as
indication of statistically signiﬁcant difference. The statis-
tical analysis was performed using SigmaStat 3.1 software
package. Since the data were not normally distributed, we
give statistical summary of the results using both the mean/
standard deviation and the median/quartile values. How-
ever, when we say ‘‘on average’’ in the text we are referring
to median values, which are more representative of the
middle of the sample and population than the mean values.
3 Results
3.1 The effect of electroporation pulse delivery
on electrocardiogram
Our program-based analysis of heartbeat characteristics
(RR interval, QRS interval, QTc interval, R wave and QRS
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123area) revealed no pathological morphological changes
caused by EP pulses in patients subjected to electroche-
motherapy. This ﬁnding was conﬁrmed independently by
two medical doctors. The signiﬁcant change, however, was
detected in RR and QRS interval duration after each
application of EP pulses (see Table 2).
The medical doctors involved in the study conﬁrmed
that EP pulses induced no heart arrhythmias. Moreover,
additional premature heartbeats were not triggered by EP
pulses in the cases where premature heartbeats were pres-
ent in ECG signal before the application of EP pulses.
The results of modeling the distribution of electric ﬁeld
and current in tissue models are presented in Tables 3 and
4. It can be seen that in the worst-case scenario (needle
hexagonal array electrodes, 10 mm depth of insertion) the
critical depth for current of 100 mA is 4.10 cm. The largest
critical depths for reversible and irreversible electropora-
tion are 1.30 and 1.07 cm, respectively, for needle row
array electrodes at insertion depth 10 mm.
Fig. 2 The geometry of tissue
models with tumor for: a plate
electrodes (length 7 mm,
thickness 0.7 mm, distance
between the electrodes d is 4, 6
or 8 mm, tumor diameter is
1 mm larger than distance
between the electrodes);
b needle row array electrodes
(diameter 0.7 mm for each
needle, distance between two
rows of electrodes d = 4 mm,
tumor radius r = 4 mm, tumor
location 0.5 mm under the skin
surface); c needle hexagonal
array electrodes (diameter
0.7 mm for each needle,
distance between two electrodes
8 mm, tumor radius
r = 15 mm)
Table 2 The change in heartbeat parameters after EP pulse delivery
Evaluated parameters Median
change
Percentile Statistical
signiﬁcance
(p) 25% 75%
RR interval (ms) -5.43 -19.60 7.72 0.006
QRS interval (ms) -1.25 -9.13 4.13 0.042
R wave amplitude (mV) 6.46 -28.50 35.20 0.414
QRS area (mV ms) 515 -671 2,010 0.091
QTc interval (ms) 1.89 -9.73 11.40 0.380
Wilcoxon Signed Rank test, n = 93
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1233.2 The algorithm for synchronization
of electroporation pulse delivery
with electrocardiogram
The performance of the algorithm for QRS detection and
synchronization of EP pulse delivery with ECG is sum-
marized in Table 5. On average, the algorithm correctly
detected 99.2% of all QRS complexes. The total number of
erroneously detected QRS complexes was 15. On average,
the algorithm would correctly deliver EP pulses in 94.6%
of normal QRS complexes. The average positive predic-
tivity for EP pulses (+Pp) was 100.0% and thus ideal.
A comparison of performance between 16 ECG signals
recorded during electrochemotherapy and 42 ECG signals
from the LTST DB database [30] was performed. The
results showed that there is not a statistically signiﬁcant
difference in the median values between all compared
performance measures (Se, +P, DER, Sep, DERp)
(0.142\p\0.924) except for the positive predictivity for
EP pulse delivery (+Pp)( p = 0.026, Mann–Whitney Rank
Sum test). This performance measure was signiﬁcantly
better for ECG signals recorded during electrochemother-
apy than for ECG signals from LTST DB database.
4 Discussion
4.1 The effect of electroporation pulse delivery
on electrocardiograms
We found no heart arrhythmias or other pathological
morphological changes of heartbeat as a consequence of
applied EP pulses. No additional premature heartbeats
were triggered even in cases when these were present in
ECG signal before the ﬁrst application of EP pulses
(signals number 11, 12 and 16). This is in agreement
with the results of the work by Al-Khadra et al. [2] that
showed no arrhythmias in association with electropora-
tion applied directly on the heart. According to the heart
strength-duration curve a very large current would be
required to cause a single premature heartbeat [7, 15, 46]
for very short EP pulse duration (the microsecond range).
Since no additional premature heartbeats were detected,
it is highly improbable that EP pulses alone could create
the inhomogeneity (altered states of depolarization–
repolarization), which is a requisite for onset of
ﬁbrillation.
The computer-based analysis demonstrated no signiﬁ-
cant statistical change in the QTc interval but a signiﬁcant
statistical decrease in the RR and QRS interval after each
application of EP pulses (Table 2). This transient effect
disappeared within 10 s after each application of EP pulses.
The RR and QRS intervals are tightly correlated because
they are both dependent on the heartbeat frequency [46].
A signiﬁcant change in QT interval is one of the most
important indicators of arrhythmias [4]. However, its value
is also dependent on the heart rate (the faster the heart rate,
the shorter the QT interval) and has to be adjusted to aid
interpretation. For this reason the QTc interval is used in
practice. A signiﬁcant change in the QTc interval would
indicate a clinically relevant effect of electrochemotherapy.
However, no such effect was observed in our study
(1.89 ms median change of QTc interval after application
of EP pulses, see Table 2).
Table 3 Calculated critical depths for electric ﬁeld and current in different plate electrode conﬁgurations
Distance between
electrodes (d) (mm)
Tumor radius
(r) (mm)
Applied
voltage (V)
Critical depth
for 100 mA (cm)
Critical depth for
200 V/cm (cm)
Critical depth for
450 V/cm (cm)
4 2.5 520 1.00 0.31 0.18
6 3.5 780 1.55 0.43 0.22
8 4.5 1,000 2.38 0.51 0.30
Table 4 Calculated critical depths for electric ﬁeld and current in needle row array and needle hexagonal array electrode conﬁgurations
Depth of
insertion (l) (mm)
Needle row array electrodes
(400 V, tumor radius r = 2 mm)
Needle hexagonal array electrodes
(730 V, tumor radius r = 15 mm)
Critical depth for
100 mA (cm)
Critical depth for
200 V/cm (cm)
Critical depth for
450 V/cm (cm)
Critical depth for
100 mA (cm)
Critical depth for
200 V/cm (cm)
Critical depth for
450 V/cm (cm)
2 1.55 0.43 0.26 2.23 0.43 –
4 2.37 0.68 0.46 2.65 0.64 0.30
6 2.94 0.90 0.70 3.20 0.87 0.54
8 3.40 1.10 0.90 3.69 1.04 0.70
10 3.79 1.30 1.07 4.10 1.25 0.93
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123Several studies suggested that there is a link between
negative emotions (e.g., anxiety) and the oscillations of RR
interval [1, 16, 24, 32, 53, 56]. The most frequently
reported symptoms in panic attacks, which are character-
ized by episodes of intense anxiety, are heart pounding and
tachycardia [16, 32]. Another possible reason for RR
interval decrease is intrinsic sympathetic activation of the
nervous system, occurring in response to stress, exercise, or
heart disease [1, 53]. The applications of electrochemo-
therapy to internal tumors could also directly affect the
cardiac tissue if tumors were located close to the heart
muscle. However, this effect is highly unlikely for current
applications of electrochemotherapy because of relatively
large distance between treated tumors and the heart (at
least several centimeters) and due to small inter-electrode
distances (8 mm or less). This assumption is further sup-
ported by the calculated critical depths for electric current
threshold values discussed later in the text. Therefore, we
suggest that the observed changes in RR interval can be
largely if not completely attributed to anxiety and stress of
the patient undergoing electrochemotherapy.
In our study almost one third (30.5%) of the 93 non-
synchronized EP applications were delivered within the
vulnerable period, which is in accordance with the fact that
the duration of the vulnerable period is around one third of
the duration of heart cycle [46]. The study of occurrence of
ventricular ﬁbrillation after atrial cardioversion performed
with transthoracic electrodes pointed out that delivery of
Table 5 ECG signals, ECG lead used, number of heartbeats of particular type, the results of QRS detection and the results of EP pulse delivery
Signal
number
Lead
name
PN d TP FN FP Se (%) +P (%) DER (%) Np TPp FNp FPp Sep (%) +Pp (%) DERp (%)
1 I 0 461 460 1 1 99.8 99.8 0.4 461 452 9 0 98.0 100.0 2.0
2 I 0 609 607 2 0 99.7 100.0 0.3 609 602 7 0 98.9 100.0 1.1
3
# I 0 462 455 7 2 98.5 99.6 1.9 462 415 47 0 89.8 100.0 10.2
4 I 0 354 351 3 2 99.2 99.4 1.4 354 334 20 0 94.4 100.0 5.7
5 I 0 1,716 1,714 2 0 99.9 100.0 0.1 1,716 1,702 14 0 99.2 100.0 0.8
6 II 0 1,822 1,819 3 0 99.8 100.0 0.2 1,822 1,809 13 0 99.3 100.0 0.7
7 II 0 1,635 1,622 13 1 99.2 99.9 0.9 1,635 1,548 87 0 94.7 100.0 5.3
8 I 0 415 415 0 0 100.0 100.0 0.0 415 412 3 0 99.3 100.0 0.7
9 I 1 1,405 1,397 8 2 99.4 99.9 0.7 1,404 1,359 45 0 96.8 100.0 3.2
10
# I 1 1,264 1,260 4 0 99.7 100.0 0.3 1,263 991 272 0 78.5 100.0 21.5
11
# III 131 795 664 131 0 83.5 100.0 16.5 664 422 242 0 63.6 100.0 36.4
12 II 17 1,348 1,330 18 0 98.7 100.0 1.3 1,331 1,307 24 0 98.2 100.0 1.8
13
# I 1 678 666 12 0 98.2 100.0 1.8 677 589 55 0 87.0 100.0 8.1
14
# I 0 1,009 1,001 8 6 99.2 99.4 1.4 1,009 540 469 0 53.5 100.0 46.5
15 I 8 798 784 14 0 98.2 100.0 1.8 790 746 44 0 94.4 100.0 5.6
16 I 18 1,384 1,358 26 1 98.1 99.9 2.0 1,366 1,291 75 0 94.5 100.0 5.5
Total – 177 16,155 15,903 252 15 – – – 15,978 14,519 1,426 0 – – –
Min – 0 354 351 0 0 83.5 99.4 0.0 354 334 3 0 53.5 100.0 0.7
25% – 0 536 534 3 0 98.4 99.8 0.3 536 437 14 0 88.4 100.0 1.5
Median – 0 904 893 8 0 99.2 100.0 1.1 900 674 45 0 94.6 100.0 5.4
75% – 5 1,395 1,378 14 2 99.7 100.0 1.8 1,385 1,333 81 0 98.5 100.0 9.1
Max – 131 1,822 1,819 131 6 100.0 100.0 16.5 1,822 1,809 469 0 99.3 100.0 46.5
Mean – 11 1,010 994 16 1 98.2 99.9 1.9 999 908 89 0 90.0 100.0 9.7
St. dev. – 33 501 504 32 2 4.0 0.2 3.9 505 516 129 0 13.6 0.0 13.6
P premature heartbeats of ventricular, supraventricular or ectopic origin; Nd total number of possible detected QRS complexes (normal and
abnormal), the sum of TP and FN; TP true positive for QRS detection (the number of correctly detected QRS complexes); FN false negative for
QRS detection (the number of missed QRS complexes); FP false positive for QRS detection (the number of false QRS detections); Se sensitivity
for QRS detection; +P positive predictivity for QRS detection; DER detection error rate for QRS detection; Np total number of normal QRS
complexes (total number of possible delivered EP pulses), the sum of TPp and FNp; TPp true positive for EP pulses (the number of EP pulses
delivered at correctly detected normal QRS complexes); FNp false negative for EP pulses (the number of correctly detected normal QRS
complexes, where no EP pulse was delivered); FPp false positive for EP pulses (the number of EP pulses delivered in the absence of correctly
detected normal QRS complexes); Sep sensitivity for EP pulses; +Pp positive predictivity for EP pulses; DERp delivery error rate for EP pulses
# ECG signals with relatively poor values of performance metrics
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123electric pulse, which was not synchronized with the R wave
consistently resulted in ventricular ﬁbrillation if the pulse
was delivered within the T wave, the vulnerable period of
the ventricles [5]. The probability for ventricular ﬁbrilla-
tion was decreased but not eliminated with the arrival of
synchronized deﬁbrillators for cardioversion [5]. A high
percentage of EP pulses delivered during the vulnerable
period in our study, when EP application is not syn-
chronized with ECG, underlines the importance of
synchronization.
The values of electric ﬁeld and current in the heart
muscle during electroporation are important for evaluation
of the danger for inducing ventricular ﬁbrillation. For tissue
models (Fig. 2) we estimated critical depths by calculating
threshold value of electric ﬁeld for reversible and irrevers-
ible electroporation of the muscle (200 and 450 V/cm,
respectively [43]), and threshold value of current for ven-
tricular ﬁbrillation (100 mA for 500 ls-long stimulus [46])
(see Tables 3 and 4). In the study by Galva ˜o et al. [17] they
showed that the threshold current that stimulates the heart
strongly depends on the age of the animal (i.e., old animals
have lower threshold levels). Due to the relatively old
patients included in our study (median value 70.8 years) we
can therefore assume that the current threshold value is
lowered. On the other hand, the EP pulses used in electro-
chemotherapy are much shorter (100 ls) and therefore the
threshold value should in theory be approximately ﬁve
times greater than for the 500 ls-long stimulus [15, 46].
Furthermore, amplitude threshold for ﬁbrillation for pulsed
direct currents is considerably higher than for alternating
currents [46]. Currently we have no conclusive information
regarding the inﬂuence of the repetition frequency of pulsed
direct currents on the threshold for ﬁbrillation. Therefore
we adopted the threshold value of 100 mA as an estimate of
true threshold value. For the needle row array and needle
hexagonal array electrodes the critical depth depends on the
depth of insertion. The results showed that for the plate
electrodes with 8 mm distance between the electrodes the
critical depth for threshold current was 2.38 cm (see
Table 3). For needle row array and needle hexagonal array
electrodes at depth of insertion of 10 mm, the critical depths
for threshold current were 3.79 and 4.10 cm, respectively
(see Table 4). The critical depth for threshold current for
plate electrodes is smaller in comparison to the needle row
array or needle hexagonal array electrodes because most of
the voltage drop occurs on the skin [33].
With electrodes positioned distantly from the heart (e.g.,
on a single limb), as in the majority of EP pulse delivery
cases (see Table 1), the current traversing the heart is
negligible and therefore a smaller risk of accidental cardiac
stimulation exists [44]. EP pulses frequently provoke
strong and painful muscle contractions [57]. In contrast
to the heart muscle, the motor neurons innervating the
skeletal muscles, which are located in relative proximity to
the electrodes, are always stimulated by EP pulses.
In electrochemotherapy applications included in our
study, plate electrodes with distances between the elec-
trodes of 6 and 8 mm and needle hexagonal array
electrodes with small depths of insertion (2 or 3 mm) were
used (see Table 1). The majority of the EP pulses were
delivered on extremities and even when delivered on the
trunk they were delivered distantly from the heart. How-
ever, two applications of EP pulses were delivered on the
chest relatively close to the heart (distance approximately
5 cm) with plate electrodes. Since the heart lies at least
3 cm beneath the skin surface [54], for the applications
involved in our study the results of modeling indicated that
it is highly unlikely that EP pulses even when applied on
the trunk directly above the heart could affect functioning
of the heart (critical depths 2.23 and 2.38 cm for needle
hexagonal array and plate electrodes, respectively). Fur-
thermore, the most vulnerable part of the heart, the apex,
lies behind the breast and is thus additionally protected
from the external stimulation by breast tissue. Additionally,
if the electrodes were located above sternum or above a rib,
the risk of affecting the heart would be further reduced due
to low conductivity of bones (range from 0.01 to 0.06 S/m)
[34] and larger dimension of sternum and ribs in compar-
ison to the distance between the electrodes. However, if the
electrodes were not located directly above the sternum or a
rib, the critical depths would be larger due to higher con-
ductivity of the underlying tissues. In this case according to
the results of modeling there exists a theoretical chance to
affect the functioning of the heart in case of deep insertion
of either needle hexagonal or row array electrodes
(approximately 4 cm for both types of electrodes at inser-
tion depth of 10 mm). This should be considered in future
applications of electrochemotherapy.
For the modeled tissues only the conductivity was taken
into account. The capacitive behavior of the tissues was
neglected since the transient effects are present only during
the charging time of the cell membrane, which lasts around
1 ls[ 39]. The membrane charging time is much shorter
compared to the EP pulse duration used in electrochemo-
therapy. It was also shown in several studies that static
analysis of the electric ﬁeld distribution during electro-
poration without taking into account the transient effects
are adequate [43, 49, 50], since after the transient effect the
tissue exhibits only ohmic behavior [13]. Using current-
voltage measurements on cells in vitro [42] or tissues in
vivo [13] it was shown that electroporation occurs after the
transient time and that the dynamic behavior at the start of
the pulses (that includes capacitive behavior of the tissue)
is not crucial for the process of electroporation. On the
other hand, this transient effect induces a rapid initial
current increase followed by an exponential decrease and a
Med Biol Eng Comput (2008) 46:745–757 753
123constant level. The applied current during electrochemo-
therapy is limited to 16 A. Since the transient effect lasts
only 1 ls and according to the heart strength-duration
curve it is very unlikely that the transient part of an EP
pulse could induce ventricular ﬁbrillation [7, 15, 46].
Since the electrode dimensions (electrode–tissue con-
tact surface area) and distance between electrodes used in
electrochemotherapy for tumors analyzed in our study are
signiﬁcantly smaller compared to the electrode dimen-
sions and positions used for cardiac deﬁbrillation, we can
assume that the differences in thorax tissues conductivi-
ties should not change the electric ﬁeld and current
distribution calculated with our numerical models.
Therefore, based on the previous studies [9, 26, 34, 43]
we can conclude that our numerical models with chosen
electrical properties can be used for the evaluation (rough
estimate) of critical electric ﬁeld and current for pro-
truding cutaneous tumors or subcutaneous tumors, which
are located immediately under the skin surface (0.5 mm
under the skin surface in our study). However, for more
deeply located tumors the exact conductivities of all tis-
sues should be incorporated in the numerical model of the
thorax.
Recently a new method of local and drug-free tissue
ablation called irreversible electroporation has been
developed for clinical use as a promising approach to
solid tumor therapy [3, 14, 35], prostate ablation [41] and
cardiac tissue ablation [28]. In these studies EP pulses
with larger amplitudes (up to 3,000 V [11]) and longer
durations (range from 100 to 24 ms) are used. The
application of EP pulses during irreversible electropora-
tion is therefore more likely to inﬂuence functioning of
the heart than EP pulses usually applied in electroche-
motherapy. However, the results of a recent study by
Lavee et al. [28] using irreversible electroporation for
epicardial atrial ablation for the treatment of atrial ﬁbril-
lation showed that ablation pulses (amplitudes of 1,500–
2,000 V, duration 100 ls, frequency 5 Hz) caused no
permanent arrhythmia or any other rhythm disturbance
apart from the rapid atrial pacing during the pulse
sequence application. The immediate resumption of sinus
rhythm following the ablation was recorded. Similarly, the
results of study by Al-Khadra et al. [2] demonstrated lack
of any evidence of spontaneous arrhythmias (reentrant or
focal) associated with electroporation of the endocardium
or the papillary muscles. In their study they presented
experimental evidence suggesting that electroporation
might even transiently reduce myocardial vulnerability to
arrhythmias. But on the other hand, they pointed out that
electric pulses of high energy are known to produce a
permanent damage, perhaps associated with electropora-
tion. This effect of electroporation may provide a substrate
for arrhythmogenesis [2]. Our results of modeling showed
that the critical depths for irreversible electroporation of
the muscle/heart (450 V/cm) are 1.07 and 0.93 cm for
needle row array and needle hexagonal array electrodes,
respectively, at insertion depth 10 mm (Table 3). The
critical depth for the plate electrodes is smaller (0.30 cm
for 8 mm distance between the electrodes). Since the heart
lies at least 3 cm beneath the skin surface [54], for the
applications involved in our study the results of model-
ing indicated that it is impossible to affect functioning of
the heart by irreversible electroporation even when EP
pulses were applied on the trunk directly above the heart.
That would not be the case for electrochemotherapy
treatment of internal tumors located close to the heart
muscle.
Considering these facts, it is nevertheless advisable to
incorporate synchronization of EP pulse delivery with ECG
in medical equipment for electroporation in order to
maximize safety of the patients especially in future clinical
applications. Synchronization of EP pulse delivery with the
refractory period of the cardiac cycle is always advisable
whenever there is a possibility of EP pulses inﬂuencing the
functioning of the heart.
4.2 The algorithm for synchronization
of electroporation pulse delivery
with electrocardiogram
The algorithm for QRS detection and EP pulse delivery
reliably detected QRS complexes in all signals recorded
during electrochemotherapy (see Table 5). The algorithm
would allow for EP pulse delivery only for correctly
identiﬁed heartbeats with no abnormalities. The perfor-
mance of our algorithm for QRS detection is similar to that
of some other detectors with comparably simple algorithms
[6, 47]. The algorithm performed poorly (large DER,
marked with # in Table 5) for ECG signals with either very
unstable R wave amplitudes or RR intervals, or heavy
contamination with high-frequency noise with amplitudes
similar to R wave, or presence of premature heartbeats not
satisfying the dynamic requirements within the QRS
complex [12, 29]. In total we found 15 false positive
detections (FP), which were caused by the occurrence of
transient noise having the morphology and the time of
appearance so similar to a normal QRS complex that the
algorithm could not distinguish them. Many of the false
negative detections (FN) were due to our self-imposed
strict requirements for as few as possible false positive
detections (FP).
The most appropriate time for EP pulse delivery is
before the onset of the vulnerable period since the vul-
nerable period can sometimes be prolonged (e.g., after
premature heartbeat) [46]. Thus delivery of EP pulses
immediately after the R wave detection but within the QRS
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123complex is the most reasonable. The delivery of EP pulses
during the vulnerable period of the atria does not present a
serious threat for the patient’s life. The hemodynamic
effects of atrial ﬂutter and ﬁbrillation, which could be
potentially caused by EP pulses during the vulnerable
period of the atria, are slim and patients are frequently
unaware of them [46]. The time reserve for safe EP pulse
delivery after the R wave detection and before the onset of
the vulnerable period of the ventricles is approximately
60 ms. This time reserve is long enough for safe EP pulse
delivery by plate or needle row electrodes and even avoids
the vulnerable period of the atria. The requirement for
avoiding the delivery of EP pulses at the moments of
potential danger for the patient would be fulﬁlled excel-
lently as indicated by the ideal +Pp values for all ECG
signals (see Table 5). However, when using hexagonal
electrodes the synchronization becomes irrelevant due to
200 ms-long EP pulse sequence which extends into the
vulnerable period of the atria and ventricles. Therefore, a
modiﬁcation of the existing EP pulse delivery protocol for
hexagonal electrodes would be needed for safer application
in the immediate vicinity of the heart. The suggested
solution is to delay the delivery of EP pulses by approxi-
mately one half of the current RR interval, which would
result in EP pulses being delivered after the vulnerable
period provided that the following heartbeat was normal.
However, delayed EP pulses would be delivered exactly
within the vulnerable period in case of the appearance of
premature heartbeat. The other possibility is to synchronize
the switching between the electrodes and partial pulse
delivery with ECG.
The statistical comparison of performance of the algo-
rithm between ECG signals recorded during
electrochemotherapy and ECG signals from the LTST DB
database [30] generally showed no statistically signiﬁcant
differences except for positive predictivity for EP pulse
delivery (+Pp). This performance measure was signiﬁ-
cantly better for ECG signals recorded during
electrochemotherapy than for ECG signals from LTST DB
database thus showing that the algorithm was developed
for worser conditions than encountered during clinical
application of electroporation. In spite of numerous ar-
rhythmias in some ECG signals from the LTST DB
database the algorithm performed excellently [30]. The
clinical electrochemotherapy was so far indicated only for
patients without clinically signiﬁcant or severe heart dis-
ease, which reﬂects in ideal value +Pp = 100% in all ECG
signals recorded during electrochemotherapy. However,
mostly old patients are included in electrochemotherapy
treatment nowadays because of the emerging need for
palliative treatment of tumors with electrochemotherapy.
With the increasing age of the patients, the probability for
encountering pathological ECG is also increasing,
therefore, the synchronization of EP pulse delivery with
ECG would maximize safety of the patient.
5 Conclusions
Currently used electroporation protocols could interfere
with functioning of the heart although no such practical
evidence exists till now. Because no systematic study
regarding this topic has been done yet, we examined in our
study the effects of EP pulses on functioning of the heart.
We measured ECG signals during electrochemotherapy
and analyzed their characteristics. We found no arrhyth-
mias or other pathological morphological changes due to
application of EP pulses. The only demonstrated effect of
EP pulses on ECG is a transient RR interval decrease. The
facts contributing to a belief that EP pulse delivery during
electrochemotherapy cannot affect functioning of the heart
are: short EP pulse duration, use of direct current, appli-
cation mainly on locations relatively distant from the heart
(i.e., on extremities), and small inter-electrode distance. On
the other hand, there are some open issues regarding
electrochemotherapy that need to be considered, for
example: EP pulses delivered by plate or needle row
electrodes that are not synchronized with ECG could be
delivered within the vulnerable period, EP pulses delivered
by hexagonal electrodes mainly coincide within the vul-
nerable period, the threshold levels of the heart for elderly
patients are lowered, possible use of electrochemotherapy
on patients with clinically signiﬁcant heart disease, new
applications with longer durations and/or higher ampli-
tudes of EP pulses as well as applications involving
endoscopic or surgical means to access internal tumors are
being developed. Even though no practical evidence for
electroporation having an effect on functioning of the heart
has been observed so far, we can still maximize safety of
the patients by incorporating the algorithm for synchroni-
zation of EP pulse delivery with ECG in medical
equipment for EP pulse delivery. The usual application of
eight EP pulses with duration 100 ls each can beneﬁt from
synchronizing delivery of EP pulses with electrocardio-
gram but this is not the case for hexagonal electrodes or
combination of high- and low-voltage EP pulses and pulses
with higher amplitudes as used in tumor tissue ablation by
irreversible electroporation.
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